Current Report Filing (8-k)
March 22 2021 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 18, 2021
Trevi Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-38886
|
|
45-0834299
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
195 Church Street, 14th Floor
New Haven, Connecticut
|
|
06510
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (203)
304-2499
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, $0.001 par value per share
|
|
TRVI
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On March 18, 2021, Christopher Seiter notified Trevi Therapeutics, Inc. (the
Company) of his intention to resign from his position as Chief Financial Officer of the Company, effective April 2, 2021. Upon the effectiveness of Mr. Seiters resignation, Jennifer Good, the Companys President and
Chief Executive Officer, will assume the role of principal financial officer of the Company.
Ms. Good, 56, is the Companys co-founder and has served as a member of the board of directors and as the President and Chief Executive Officer since the Companys inception in March 2011. Previously, Ms. Good served at Penwest
Pharmaceuticals Co., a biopharmaceutical company, from 1997 to 2010, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Ms. Good has served on the board of
Rhythm Pharmaceuticals, a publicly-traded biopharmaceutical company, since June 2019. Previously, Ms. Good served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired by
Catalent, Inc. in August 2018. Ms. Good has also served as a board member of the Friedreichs Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreichs Ataxia, since 2011.
Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is
currently inactive.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
TREVI THERAPEUTICS, INC.
|
|
|
|
|
Date: March 22, 2021
|
|
|
|
By:
|
|
/s/ Jennifer Good
|
|
|
|
|
|
|
Jennifer Good
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024